tradingkey.logo
tradingkey.logo
Search

Following Positive Phase 2A Pancreatic Cancer Data, Can-Fite Advances Namodenoson Into Phase 2B Combination Study With Immunotherapy

ReutersMay 13, 2026 11:01 AM
facebooktwitterlinkedin
View all comments0

Can Fite Biopharma Ltd CANF.TA:

  • FOLLOWING POSITIVE PHASE 2A PANCREATIC CANCER DATA, CAN-FITE ADVANCES NAMODENOSON INTO PHASE 2B COMBINATION STUDY WITH IMMUNOTHERAPY

  • CAN FITE BIOPHARMA LTD - TO ADVANCE NAMODENOSON INTO PHASE 2B PANCREATIC CANCER STUDY WITH IMMUNOTHERAPY

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

Tradingkey
KeyAI